Characterization of the Inflammatory Properties of Actively Released HMGB1 in Juvenile Idiopathic Arthritis

Antioxidants and Redox Signaling

Volumn 24, Issue 12, 2016, Pages 605-619

  Lundbäck, Peter ^a   Stridh, Pernilla ^a   Klevenvall, Lena ^a   Jenkins, Rosalind E ^b   Fischer, Marie ^a   Sundberg, Erik ^a   Andersson, Ulf ^a   Antoine, Daniel J ^b   Harris, Helena Erlandsson ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOATTRACTANT; CYSTEINE; DISULFIDE; HIGH MOBILITY GROUP B1 PROTEIN; LACTATE DEHYDROGENASE; LYSINE; HMGB1 PROTEIN, HUMAN;

ACETYLATION; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LIQUID CHROMATOGRAPHY; MALE; METHYLATION; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN PROCESSING; SYNOVIAL FLUID; TANDEM MASS SPECTROMETRY; INFLAMMATION; METABOLISM; PRESCHOOL CHILD;

ADOLESCENT; ARTHRITIS, JUVENILE; CHILD; CHILD, PRESCHOOL; HMGB1 PROTEIN; HUMANS; INFLAMMATION;

EID: 84966333750     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2014.6039     Document Type: Article

References (49)

1. Antoine DJ, Dear JW, Starkey-Lewis P, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, and Park BK. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. Hepatology 58: 777-787, 2013.
2. Antoine DJ, Harris HE, Andersson U, Tracey KJ, and Bianchi ME. A systematic nomenclature for the redox states of high mobility group box (HMGB) proteins. Mol Med 20: 135-137, 2014.
3. Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, and Park BK. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 56: 1070-1079, 2012.
4. Antoine DJ, Williams DP, Kipar A, Jenkins RE, Regan SL, Sathish JG, Kitteringham NR, and Park BK. High-mobility group box-1 protein and keratin-18, circulating serum proteins informative of acetaminophen-induced necrosis and apoptosis in vivo. Toxicol Sci 112: 521-531, 2009.
5. Antoine DJ, Williams DP, Kipar A, Laverty H, and Park BK. Diet restriction inhibits apoptosis and HMGB1 oxidation and promotes inflammatory cell recruitment during acetaminophen hepatotoxicity. Mol Med 16: 479-490, 2010.
6. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, and Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 22: 5551-5560, 2003.
7. Chen R, Hou W, Zhang Q, Kang R, Fan XG, and Tang D. Emerging role of high-mobility group box 1 (HMGB1) in liver diseases. Mol Med 19: 357-366, 2013.
8. Chung YL, Lee MY, Wang AJ, and Yao LF. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol Ther 8: 707-717, 2003.
9. Diener KR, Al-Dasooqi N, Lousberg EL, and Hayball JD. The multifunctional alarmin HMGB1 with roles in the pathophysiology of sepsis and cancer. Immunol Cell Biol 91: 443-450, 201.
10. Entezari M, Javdan M, Antoine DJ, Morrow DM, Sitapara RA, Patel V, Wang M, Sharma L, Gorasiya S, Zur M, Wu W, Li J, Yang H, Ashby CR, Thomas D, Wang H, and Mantell LL. Inhibition of extracellular HMGB1 attenuates hyperoxia-induced inflammatory acute lung injury. Redox Biol 2: 314-322, 2014.
11. Evankovich J, Cho SW, Zhang R, Cardinal J, Dhupar R, Zhang L, Klune JR, Zlotnicki J, Billiar T, and Tsung A. High mobility group box 1 release from hepatocytes during ischemia and reperfusion injury is mediated by decreased histone deacetylase activity. J Biol Chem 285: 39888-39897, 2010.
12. Garcia-Arnandis I, Guillen MI, Gomar F, Pelletier JP, Martel-Pelletier J, and Alcaraz MJ. High mobility group box 1 potentiates the pro-inflammatory effects of interleukin-1beta in osteoarthritic synoviocytes. Arthritis Res Ther 12: R165, 2010.
13. Gardella S, Andrei C, Ferrera D, Lotti LV, Torrisi MR, Bianchi ME, and Rubartelli A. The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep 3: 995-1001, 2002.
14. Ge X, Antoine DJ, Lu Y, Arriazu E, Leung TM, Klepper AL, Branch AD, Fiel MI, and Nieto N. High-mobility group box-1 (HMGB1) participates in the pathogenesis of alcoholic liver disease (ALD). J Biol Chem 289: 22672-22691, 2014.
15. Glozak MA, Sengupta N, Zhang X, and Seto E. Acetylation and deacetylation of non-histone proteins. Gene 363: 15-23, 2005.
16. Hamada T, Torikai M, Kuwazuru A, Tanaka M, Horai N, Fukuda T, Yamada S, Nagayama S, Hashiguchi K, Sunahara N, Fukuzaki K, Nagata R, Komiya S, Maruyama I, and Abeyama K. Extracellular high mobility group box chromosomal protein 1 is a coupling factor for hypoxia and inflammation in arthritis. Arthritis Rheum 58: 2675-2685, 2008.
17. Hsieh IN, Liou JP, Lee HY, Lai MJ, Li YH, and Yang CR. Preclinical anti-arthritic study and pharmacokinetic properties of a potent histone deacetylase inhibitor MPT0G009. Cell Death Dis 5: e1166, 2014.
18. Ito I, Fukazawa J, and Yoshida M. Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 282: 16336-16344, 2007.
19. Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, and Ferguson TA. Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of highmobility group box-1 protein. Immunity 29: 21-32, 2008.
20. Kim S, Kim SY, Pribis JP, Lotze M, Mollen KP, Shapiro R, Loughran P, Scott MJ, and Billiar TR. Signaling of high mobility group box 1 (HMGB1) through toll-like receptor 4 in macrophages requires CD14. Mol Med 19: 88-98, 2013.
21. Kokkola R, Sundberg E, Ulfgren AK, Palmblad K, Li J, Wang H, Ulloa L, Yang H, Yan XJ, Furie R, Chiorazzi N, Tracey KJ, Andersson U, and Harris HE. High mobility group box chromosomal protein 1: a novel proinflammatory mediator in synovitis. Arthritis Rheum 46: 2598-2603, 2002.
22. Lamkanfi M, Sarkar A, Vande Walle L, Vitari AC, Amer AO, Wewers MD, Tracey KJ, Kanneganti TD, and Dixit VM. Inflammasome-dependent release of the alarmin HMGB1 in endotoxemia. J Immunol 185: 4385-4392, 2010.
23. Li J, Kokkola R, Tabibzadeh S, Yang R, Ochani M, Qiang X, Harris HE, Czura CJ, Wang H, Ulloa L, Warren HS, Moldawer LL, Fink MP, Andersson U, Tracey KJ, and Yang H. Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol Med 9: 37-45, 2003.
24. Lu B, Antoine DJ, Kwan K, Lundback P, Wahamaa H, Schierbeck H, Robinson M, Van Zoelen MA, Yang H, Li J, Erlandsson-Harris H, Chavan SS, Wang H, Andersson U, and Tracey KJ. JAK/STAT1 signaling promotes HMGB1 hyperacetylation and nuclear translocation. Proc Natl Acad Sci U S A 111: 3068-3073, 2014.
25. Lu B, Nakamura T, Inouye K, Li J, Tang Y, Lundback P, Valdes-Ferrer SI, Olofsson PS, Kalb T, Roth J, Zou Y, Erlandsson-Harris H, Yang H, Ting JP, Wang H, Andersson U, Antoine DJ, Chavan SS, Hotamisligil GS, and Tracey KJ. Novel role of PKR in inflammasome activation and HMGB1 release. Nature 488: 670-674, 2012.
26. Mitroulis I, Kambas K, Chrysanthopoulou A, Skendros P, Apostolidou E, Kourtzelis I, Drosos GI, Boumpas DT, and Ritis K. Neutrophil extracellular trap formation is associated with IL-1beta and autophagy-related signaling in gout. PLoS One 6: e29318, 2011.
27. Nystrom S, Antoine DJ, Lundback P, Lock JG, Nita AF, Hogstrand K, Grandien A, Erlandsson-Harris H, Andersson U, and Applequist SE. TLR activation regulates damage-associated molecular pattern isoforms released during pyroptosis. EMBO J 32: 86-99, 2013.
28. Palmblad K, Schierbeck H, Sundberg E, Horne AC, Harris HE, Henter JI, Antoine DJ, and Andersson U. High systemic levels of the cytokine-inducing HMGB1 isoform secreted in severe macrophage activation syndrome. Mol Med 2014 [Epub ahead of print]; DOI: 10.2119/molmed.2014.00183.
29. Pascual V, Allantaz F, Arce E, Punaro M, and Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201: 1479-1486, 2005.
30. Pullerits R, Jonsson IM, Verdrengh M, Bokarewa M, Andersson U, Erlandsson-Harris H, and Tarkowski A. High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum 48: 1693-1700, 2003.
31. Qin YH, Dai SM, Tang GS, Zhang J, Ren D, Wang ZW, and Shen Q. HMGB1 enhances the proinflammatory activity of lipopolysaccharide by promoting the phosphorylation of MAPK p38 through receptor for advanced glycation end products. J Immunol 183: 6244-6250, 2009.
32. Rodrigues AV, Maggs JL, McWilliam SJ, Pirmohamed M, Coen M, Wilson ID, Park BK, and Antoine DJ. Quantification of urinary mevalonic acid as a biomarker of HMG- CoA reductase activity by a novel translational LC-MS/MS method. Bioanalysis 6: 919-933, 2014.
33. Rubartelli A, Gattorno M, Netea MG, and Dinarello CA. Interplay between redox status and inflammasome activation. Trends Immunol 32: 559-566, 2011.
34. Schierbeck H, Lundback P, Palmblad K, Klevenvall L, Erlandsson-Harris H, Andersson U, and Ottosson L. Monoclonal anti-HMGB1 (high mobility group box chromosomal protein 1) antibody protection in two experimental arthritis models. Mol Med 17: 1039-1044, 2011.
35. Schierbeck H, Pullerits R, Pruunsild C, Fischer M, Holzinger D, Laestadius A, Sundberg E, and Harris HE. HMGB1 levels are increased in patients with juvenile idiopathic arthritis, correlate with early onset of disease, and are independent of disease duration. J Rheumatol 40: 1604-1613, 2013.
36. Schiraldi M, Raucci A, Munoz LM, Livoti E, Celona B, Venereau E, Apuzzo T, De Marchis F, Pedotti M, Bachi A, Thelen M, Varani L, Mellado M, Proudfoot A, Bianchi ME, and Uguccioni M. HMGB1 promotes recruitment of inflammatory cells to damaged tissues by forming a complex with CXCL12 and signaling via CXCR4. J Exp Med 209: 551-563, 2012.
37. Tang D, Shi Y, Kang R, Li T, Xiao W, Wang H, and Xiao X. Hydrogen peroxide stimulates macrophages and monocytes to actively release HMGB1. J Leukoc Biol 81: 741-747, 2007.
38. Taniguchi N, Kawahara K, Yone K, Hashiguchi T, Yamakuchi M, Goto M, Inoue K, Yamada S, Ijiri K, Matsunaga S, Nakajima T, Komiya S, and Maruyama I. High mobility group box chromosomal protein 1 plays a role in the pathogenesis of rheumatoid arthritis as a novel cytokine. Arthritis Rheum 48: 971-981, 2003.
39. van Beijnum JR, Buurman WA, and Griffioen AW. Convergence and amplification of toll-like receptor (TLR) and receptor for advanced glycation end products (RAGE) signaling pathways via high mobility group B1 (HMGB1). Angiogenesis 11: 91-99, 2008.
40. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F, Liu J, Antonelli A, Preti A, Raeli L, Shams SS, Yang H, Varani L, Andersson U, Tracey KJ, Bachi A, Uguccioni M, and Bianchi ME. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 209: 1519-1528, 2012.
41. Vojinovic J and Damjanov N. HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol Med 17: 397-403, 2011.
42. Wahamaa H, Schierbeck H, Hreggvidsdottir HS, Palmblad K, Aveberger AC, Andersson U, and Harris HE. High mobility group box protein 1 in complex with lipopolysaccharide or IL-1 promotes an increased inflammatory phenotype in synovial fibroblasts. Arthritis Res Ther 13: R136, 2011.
43. Wang H, Vishnubhakat JM, Bloom O, Zhang M, Ombrellino M, Sama A, and Tracey KJ. Proinflammatory cytokines (tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 126: 389-392, 1999.
44. Yang H, Antoine DJ, Andersson U, and Tracey KJ. The many faces of HMGB1: molecular structure-functional activity in inflammation, apoptosis, and chemotaxis. J Leukoc Biol 93: 865-873, 2013.
45. Yang H, Hreggvidsdottir HS, Palmblad K, Wang H, Ochani M, Li J, Lu B, Chavan S, Rosas-Ballina M, Al-Abed Y, Akira S, Bierhaus A, Erlandsson-Harris H, Andersson U, and Tracey KJ. A critical cysteine is required for HMGB1 binding to Toll-like receptor 4 and activation of macrophage cytokine release. Proc Natl Acad Sci U S A 107: 11942-11947, 2010.
46. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME, Al-Abed Y, Andersson U, Tracey KJ, and Antoine DJ. Redox modification of cysteine residues regulates the cytokine activity of high mobility group box-1 (HMGB1). Mol Med 18: 250-259, 2012.
47. Yang H and Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 1799: 149-156, 2010.
48. Yu M, Wang H, Ding A, Golenbock DT, Latz E, Czura CJ, Fenton MJ, Tracey KJ, and Yang H. HMGB1 signals through toll-like receptor (TLR) 4 and TLR2. Shock 26: 174-179, 2006.
49. Zou JY and Crews FT. Release of neuronal HMGB1 by Ethanol through decreased HDAC activity activates brain neuroimmune signaling. PLoS One 9: e87915, 2014.